Product NDC: | 59417-107 |
Proprietary Name: | Vyvanse |
Non Proprietary Name: | lisdexamfetamine dimesylate |
Active Ingredient(s): | 70 mg/1 & nbsp; lisdexamfetamine dimesylate |
Administration Route(s): | ORAL |
Dosage Form(s): | CAPSULE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 59417-107 |
Labeler Name: | Shire LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA021977 |
Marketing Category: | NDA |
Start Marketing Date: | 20070223 |
Package NDC: | 59417-107-10 |
Package Description: | 100 CAPSULE in 1 BOTTLE (59417-107-10) |
NDC Code | 59417-107-10 |
Proprietary Name | Vyvanse |
Package Description | 100 CAPSULE in 1 BOTTLE (59417-107-10) |
Product NDC | 59417-107 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | lisdexamfetamine dimesylate |
Dosage Form Name | CAPSULE |
Route Name | ORAL |
Start Marketing Date | 20070223 |
Marketing Category Name | NDA |
Labeler Name | Shire LLC |
Substance Name | LISDEXAMFETAMINE DIMESYLATE |
Strength Number | 70 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Central Nervous System Stimulant [EPC],Central Nervous System Stimulation [PE] |